Nuclear factor-κB (NF-κB) is a transcription factor responsible for modulating the expression of many genes involved in immune response, inflammatory process, cell growth and survival. A functional and common promoter polymorphism of the NF-κB1 (NFKB1) gene leads to alteration in the activation pattern and expression of NF-κB, and thus, is probably associated with carcinogenesis. The aim of this study was to detect the importance and the frequency of NFKB1 –94 insertion/deletion ATTG promoter polymorphism in patients with gastroenteropancreatic neuroendocrine tumor. A case-control cohort including 50 patients with gastroenteropancreatic neuroendocrine tumor and 100 healthy controls was genotyped with the polymerase chain reaction method. Polymerase chain reaction products were analyzed in agarose gel electrophoresis and processed with the Van91I restriction enzyme. There are 2 cleavage points on the amplified region. When ATTG insertion or deletion is present, the function of restriction enzyme changes. Thirty patients (60%) had ID (insertion/deletion), 18 (36%) had II (insertion/insertion) and 2 (4%) had DD (deletion/deletion) genotypes. Fifty-eight of the control group (58%) had ID, 30 (30%) had II and 12 (12%) had DD genotypes. The frequencies of D and I alleles were 34 and 66 in the study group, and 82 and 118 in the control group, respectively. Although the frequencies of I and D alleles and genotype distribution did not differ between the study and control groups, there seem to be important differences concerning the DD genotype analyses of the NFKB1 –94ins/delATTG promoter polymorphism between patients with pancreatic neuroendocrine tumor and those with carcinoid tumor. This may support the view that the genetics of carcinoid tumors and pancreatic neuroendocrine tumors are different and should be further studied.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.